ChromaDex (NASDAQ:CDXC – Get Rating) was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Wednesday.
Several other brokerages also recently weighed in on CDXC. LADENBURG THALM/SH SH lowered their price target on shares of ChromaDex from $7.50 to $6.60 in a report on Thursday, May 11th. HC Wainwright cut their price objective on shares of ChromaDex from $5.50 to $5.00 and set a “buy” rating on the stock in a research report on Monday, March 13th.
ChromaDex Stock Down 4.7 %
Shares of CDXC stock opened at $1.43 on Wednesday. The company has a 50 day moving average price of $1.47 and a 200-day moving average price of $1.66. ChromaDex has a 52 week low of $1.15 and a 52 week high of $2.37. The firm has a market capitalization of $107.21 million, a PE ratio of -9.53 and a beta of 1.79.
Institutional Trading of ChromaDex
Hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in shares of ChromaDex by 9.5% during the first quarter. Vanguard Group Inc. now owns 2,781,437 shares of the company’s stock valued at $6,842,000 after buying an additional 240,414 shares during the last quarter. Tieton Capital Management LLC grew its stake in shares of ChromaDex by 20.6% during the 4th quarter. Tieton Capital Management LLC now owns 2,745,024 shares of the company’s stock worth $4,612,000 after purchasing an additional 469,429 shares during the period. State Street Corp grew its stake in shares of ChromaDex by 4.1% during the 1st quarter. State Street Corp now owns 932,526 shares of the company’s stock worth $2,294,000 after purchasing an additional 36,308 shares during the period. Millennium Management LLC acquired a new stake in shares of ChromaDex during the 2nd quarter worth approximately $1,275,000. Finally, Renaissance Technologies LLC lifted its position in shares of ChromaDex by 76.0% during the 2nd quarter. Renaissance Technologies LLC now owns 739,900 shares of the company’s stock valued at $1,236,000 after buying an additional 319,399 shares in the last quarter. 42.81% of the stock is owned by hedge funds and other institutional investors.
ChromaDex Company Profile
Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.
- Get a free copy of the StockNews.com research report on ChromaDex (CDXC)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.